Abstract |
Clomipramine ushered in a new age of pharmacotherapy for obsessive-compulsive disorders, and it also facilitated our understanding of the biological aspects of obsessive-compulsive disorder, focusing on the serotonergic systems. The introduction of selective serotonin reuptake inhibitors has led to great progress in the pharmacological study of obsessive-compulsive disorder based on the serotonin hypothesis. Currently, selective serotonin reuptake inhibitors are positioned as a first-line drug of obsessive-compulsive disorder pharmacotherapy in the various guidelines and algorithms. Among six different selective serotonin reuptake inhibitors ( paroxetine, sertraline, fluoxetine, fluvoxamine, citalopram, escitalopram) that are available worldwide, paroxetine has the broadest treatment spectrum and promises great benefits not only for obsessive-compulsive disorder patients, but also for those with comorbid depression and/or various kinds of anxiety disorders. This paper presents several clinical trials of paroxetine carried out, and discusses and reviews the therapeutic strategies for obsessive-compulsive disorder.
|
Authors | Kunitoshi Kamijima, Mayumi Aoki |
Journal | Expert review of neurotherapeutics
(Expert Rev Neurother)
Vol. 6
Issue 7
Pg. 945-56
(Jul 2006)
ISSN: 1744-8360 [Electronic] England |
PMID | 16831110
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antidepressive Agents, Second-Generation
- Paroxetine
|
Topics |
- Antidepressive Agents, Second-Generation
(administration & dosage, adverse effects)
- Clinical Trials as Topic
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Humans
- Obsessive-Compulsive Disorder
(drug therapy, prevention & control)
- Paroxetine
(administration & dosage, adverse effects)
- Practice Patterns, Physicians'
- Treatment Outcome
|